Johnson&Johnson

Fourth Quarter 2024

Other Financial Disclosures

Table of Contents

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

	FOURTH QUARTER					TWELVE MONTHS				
				Percent Change					Percent Change	
	2024	2023	Total	Operations	Currency	2024	2023	Total	Operations	Currency
Sales to customers by segment of business										
Innovative Medicine [1]										
U.S.	$ 8,977	8,079	11.1 %	11.1	-	$ 33,970	31,169	9.0 %	9.0	-
International	5,355	5,643	(5.1)	(1.0)	(4.1)	22,994	23,590	(2.5)	1.3	(3.8)
	14,332	13,722	4.4	6.1	(1.7)	56,964	54,759	4.0	5.7	(1.7)
Innovative Medicine excluding COVID-19 Vaccine [1]										
U.S.	8,977	8,079	11.1	11.1	-	33,970	31,169	9.0	9.0	-
International	5,355	5,599	(4.4)	(0.3)	(4.1)	22,796	22,473	1.4	5.5	(4.1)
	14,332	13,678	4.8	6.5	(1.7)	56,766	53,642	5.8	7.5	(1.7)
MedTech										
U.S.	4,227	3,930	7.6	7.6	-	16,332	15,275	6.9	6.9	-
International	3,961	3,743	5.8	7.6	(1.8)	15,525	15,125	2.6	5.4	(2.8)
	8,188	7,673	6.7	7.6	(0.9)	31,857	30,400	4.8	6.2	(1.4)
U.S.	13,204	12,009	10.0	10.0	-	50,302	46,444	8.3	8.3	-
International	9,316	9,386	(0.7)	2.5	(3.2)	38,519	38,715	(0.5)	2.9	(3.4)
Worldwide	22,520	21,395	5.3	6.7	(1.4)	88,821	85,159	4.3	5.9	(1.6)
U.S.	13,204	12,009	10.0	10.0	-	50,302	46,444	8.3	8.3	-
International	9,316	9,342	(0.3)	2.9	(3.2)	38,321	37,598	1.9	5.5	(3.6)
Worldwide excluding COVID-19 Vaccine [1]	$ 22,520	21,351	5.5 %	6.9	(1.4)	$ 88,623	84,042	5.5 %	7.0	(1.5)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

[1] Refer to supplemental sales information schedules

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FOURTH QUARTER					TWELVE MONTHS				
			Percent Change					Percent Change		
	2024	2023	Total	Operations	Currency	2024	2023	Total	Operations	Currency
Sales to customers by geographic area										
U.S.	**$ 13,204**	**12,009**	10.0 %	10.0	-	**$ 50,302**	**46,444**	8.3 %	8.3	-
Europe	**4,921**	**4,962**	(0.8)	(0.2)	(0.6)	**20,212**	**20,410**	(1.0)	(0.6)	(0.4)
Western Hemisphere excluding U.S.	**1,135**	**1,166**	(2.7)	17.6	(20.3)	**4,714**	**4,549**	3.6	20.4	(16.8)
Asia-Pacific, Africa	**3,260**	**3,258**	0.1	0.9	(0.8)	**13,593**	**13,756**	(1.2)	2.3	(3.5)
International	**9,316**	**9,386**	(0.7)	2.5	(3.2)	**38,519**	**38,715**	(0.5)	2.9	(3.4)
Worldwide	**$ 22,520**	**21,395**	5.3 %	6.7	(1.4)	**$ 88,821**	**85,159**	4.3 %	5.9	(1.6)

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FOURTH QUARTER					TWELVE MONTHS				
			Percent Change					Percent Change		
	2024	2023	Total	Operations	Currency	2024	2023	Total	Operations	Currency
Sales to customers by geographic area (ex. COVID-19 Vaccine)										
U.S.*	**$ 13,204**	**12,009**	10.0 %	10.0	-	**$ 50,302**	**46,444**	8.3 %	8.3	-
Europe[(1)]	**4,921**	**4,918**	0.1	0.7	(0.6)	**20,014**	**19,293**	3.7	4.1	(0.4)
Western Hemisphere excluding U.S.*	**1,135**	**1,166**	(2.7)	17.6	(20.3)	**4,714**	**4,549**	3.6	20.4	(16.8)
Asia-Pacific, Africa*	**3,260**	**3,258**	0.1	0.9	(0.8)	**13,593**	**13,756**	(1.2)	2.3	(3.5)
International	**9,316**	**9,342**	(0.3)	2.9	(3.2)	**38,321**	**37,598**	1.9	5.5	(3.6)
Worldwide	**$ 22,520**	**21,351**	5.5 %	6.9	(1.4)	**$ 88,623**	**84,042**	5.5 %	7.0	(1.5)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

[(1)] Refer to supplemental sales information schedules
*No COVID-19 Vaccine sales

INNOVATIVE MEDICINE SEGMENT [2]	REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER 2024	2023	% Change Reported	Operational [1]	Currency	REPORTED SALES vs. PRIOR PERIOD ($MM) TWELVE MONTHS 2024	2023	% Change Reported	Operational [1]	Currency
IMMUNOLOGY										
US	$ 2,856	3,033	-5.9%	-5.9%	-	$ 11,355	11,539	-1.6%	-1.6%	-
Intl	1,383	1,562	-11.5%	-6.5%	-5.0%	6,473	6,513	-0.6%	4.0%	-4.6%
WW	4,238	4,595	-7.8%	-6.1%	-1.7%	17,828	18,052	-1.2%	0.4%	-1.6%
REMICADE										
US	231	294	-21.4%	-21.4%	-	1,009	1,143	-11.7%	-11.7%	-
US Exports [3]	9	35	-73.3%	-73.3%	-	98	147	-33.0%	-33.0%	-
Intl	117	100	16.5%	22.9%	-6.4%	497	549	-9.5%	-5.0%	-4.5%
WW	359	429	-16.5%	-15.0%	-1.5%	1,605	1,839	-12.8%	-11.4%	-1.4%
SIMPONI / SIMPONI ARIA										
US	262	258	1.3%	1.3%	-	1,082	1,124	-3.8%	-3.8%	-
Intl	321	244	32.1%	44.2%	-12.1%	1,108	1,073	3.3%	13.2%	-9.9%
WW	583	502	16.2%	22.1%	-5.9%	2,190	2,197	-0.3%	4.5%	-4.8%
STELARA										
US	1,699	1,786	-4.9%	-4.9%	-	6,720	6,966	-3.5%	-3.5%	-
Intl	650	967	-32.7%	-29.6%	-3.1%	3,641	3,892	-6.4%	-3.3%	-3.1%
WW	2,349	2,753	-14.7%	-13.6%	-1.1%	10,361	10,858	-4.6%	-3.4%	-1.2%
TREMFYA										
US	654	657	-0.6%	-0.6%	-	2,443	2,147	13.7%	13.7%	-
Intl	295	252	16.9%	21.7%	-4.8%	1,227	999	22.8%	27.6%	-4.8%
WW	949	910	4.2%	5.6%	-1.4%	3,670	3,147	16.6%	18.1%	-1.5%
OTHER IMMUNOLOGY										
US	0	2	*	*	-	3	11	-74.1%	-74.1%	-
Intl	0	0	-	-	-	0	0	-	-	-
WW	0	2	*	*	*	3	11	-74.1%	-74.1%	-
INFECTIOUS DISEASES										
US	331	353	-6.4%	-6.4%	-	1,354	1,500	-9.8%	-9.8%	-
Intl	443	498	-11.2%	-9.8%	-1.4%	2,042	2,918	-30.0%	-29.3%	-0.7%
WW	774	852	-9.2%	-8.4%	-0.8%	3,396	4,418	-23.1%	-22.7%	-0.4%
COVID-19 VACCINE										
US	0	0	-	-	-	0	0	-	-	-
Intl	0	44	*	*	*	198	1,117	-82.4%	-82.4%	0.0%
WW	0	44	*	*	*	198	1,117	-82.4%	-82.4%	0.0%
EDURANT / rilpivirine										
US	7	9	-10.1%	-10.1%	-	31	35	-10.0%	-10.0%	-
Intl	315	299	5.0%	5.6%	-0.6%	1,241	1,115	11.2%	11.2%	0.0%
WW	322	307	4.6%	5.1%	-0.5%	1,272	1,150	10.6%	10.6%	0.0%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA										
US	321	341	-5.8%	-5.8%	-	1,311	1,446	-9.4%	-9.4%	-
Intl	86	98	-12.9%	-8.9%	-4.0%	401	408	-1.7%	1.1%	-2.8%
WW	407	439	-7.4%	-6.5%	-0.9%	1,712	1,854	-7.7%	-7.1%	-0.6%
OTHER INFECTIOUS DISEASES										
US	1	4	-53.1%	-53.1%	-	11	19	-41.0%	-41.0%	-
Intl	43	58	-24.2%	-22.4%	-1.8%	203	278	-26.7%	-23.9%	-2.8%
WW	45	62	-26.1%	-24.4%	-1.7%	214	297	-27.6%	-25.0%	-2.6%

	REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER					REPORTED SALES vs. PRIOR PERIOD ($MM) TWELVE MONTHS				
			% Change					% Change		
	2024	2023	Reported	Operational [1]	Currency	2024	2023	Reported	Operational [1]	Currency
NEUROSCIENCE										
US	**1,148**	**1,022**	12.3%	12.3%	-	**4,398**	**4,065**	8.2%	8.2%	-
Intl	**628**	**780**	-19.6%	-16.8%	-2.8%	**2,718**	**3,076**	-11.6%	-7.8%	-3.8%
WW	**1,775**	**1,801**	-1.5%	-0.3%	-1.2%	**7,115**	**7,140**	-0.4%	1.3%	-1.7%
CONCERTA / Methylphenidate										
US	**33**	**39**	-12.8%	-12.8%	-	**134**	**230**	-41.7%	-41.7%	-
Intl	**125**	**142**	-11.5%	-7.7%	-3.8%	**507**	**554**	-8.4%	-4.1%	-4.3%
WW	**159**	**180**	-11.7%	-8.8%	-2.9%	**641**	**783**	-18.1%	-15.1%	-3.0%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA										
US	**796**	**733**	8.6%	8.6%	-	**3,125**	**2,897**	7.9%	7.9%	-
Intl	**267**	**278**	-4.0%	-1.8%	-2.2%	**1,097**	**1,218**	-9.9%	-7.1%	-2.8%
WW	**1,063**	**1,011**	5.1%	5.7%	-0.6%	**4,222**	**4,115**	2.6%	3.4%	-0.8%
SPRAVATO										
US	**269**	**180**	50.1%	50.1%	-	**929**	**589**	57.8%	57.8%	-
Intl	**28**	**26**	7.1%	12.5%	-5.4%	**148**	**100**	48.2%	51.2%	-3.0%
WW	**297**	**206**	44.6%	45.3%	-0.7%	**1,077**	**689**	56.4%	56.8%	-0.4%
OTHER NEUROSCIENCE										
US	**49**	**71**	-31.0%	-31.0%	-	**210**	**349**	-39.8%	-39.8%	-
Intl	**206**	**334**	-38.1%	-35.4%	-2.7%	**965**	**1,204**	-19.8%	-15.1%	-4.7%
WW	**255**	**404**	-36.9%	-34.6%	-2.3%	**1,175**	**1,553**	-24.3%	-20.7%	-3.6%
ONCOLOGY										
US	**3,019**	**2,285**	32.2%	32.2%	-	**10,854**	**8,462**	28.3%	28.3%	-
Intl	**2,476**	**2,334**	6.1%	10.6%	-4.5%	**9,926**	**9,199**	7.9%	12.1%	-4.2%
WW	**5,497**	**4,618**	19.0%	21.3%	-2.3%	**20,781**	**17,661**	17.7%	19.8%	-2.1%
CARVYKTI										
US	**304**	**145**	*	*	-	**869**	**469**	85.2%	85.2%	-
Intl	**31**	**13**	*	*	*	**94**	**30**	*	*	*
WW	**334**	**159**	*	*	*	**963**	**500**	92.7%	92.7%	0.0%
DARZALEX										
US	**1,799**	**1,395**	28.9%	28.9%	-	**6,588**	**5,277**	24.8%	24.8%	-
Intl	**1,285**	**1,155**	11.3%	17.0%	-5.7%	**5,082**	**4,467**	13.8%	19.1%	-5.3%
WW	**3,084**	**2,550**	20.9%	23.5%	-2.6%	**11,670**	**9,744**	19.8%	22.2%	-2.4%
ERLEADA										
US	**342**	**287**	19.0%	19.0%	-	**1,282**	**1,065**	20.3%	20.3%	-
Intl	**442**	**361**	22.4%	25.7%	-3.3%	**1,717**	**1,322**	29.8%	32.9%	-3.1%
WW	**784**	**647**	20.9%	22.7%	-1.8%	**2,999**	**2,387**	25.6%	27.3%	-1.7%
IMBRUVICA										
US	**250**	**255**	-2.0%	-2.0%	-	**1,020**	**1,051**	-3.0%	-3.0%	-
Intl	**481**	**533**	-9.6%	-6.8%	-2.8%	**2,018**	**2,214**	-8.8%	-6.3%	-2.5%
WW	**731**	**788**	-7.2%	-5.2%	-2.0%	**3,038**	**3,264**	-6.9%	-5.2%	-1.7%
TECVAYLI										
US	**108**	**102**	5.6%	5.6%	-	**418**	**334**	25.3%	25.3%	-
Intl	**38**	**24**	59.9%	71.6%	-11.7%	**131**	**61**	*	*	*
WW	**146**	**126**	15.8%	18.0%	-2.2%	**549**	**395**	38.8%	39.8%	-1.0%
ZYTIGA / abiraterone acetate										
US	**9**	**9**	-7.3%	-7.3%	-	**34**	**50**	-32.2%	-32.2%	-
Intl	**127**	**191**	-33.6%	-30.7%	-2.9%	**597**	**837**	-28.6%	-24.6%	-4.0%
WW	**135**	**201**	-32.4%	-29.6%	-2.8%	**631**	**887**	-28.8%	-25.0%	-3.8%
OTHER ONCOLOGY										
US	**208**	**90**	*	*	-	**643**	**215**	*	*	-
Intl	**74**	**58**	25.5%	30.6%	-5.1%	**288**	**269**	7.1%	10.4%	-3.3%
WW	**282**	**148**	90.4%	92.4%	-2.0%	**931**	**484**	92.5%	94.3%	-1.8%

	FOURTH QUARTER REPORTED SALES vs. PRIOR PERIOD ($MM)					TWELVE MONTHS REPORTED SALES vs. PRIOR PERIOD ($MM)				
			% Change					% Change		
	2024	2023	Reported	Operational [1]	Currency	2024	2023	Reported	Operational [1]	Currency
PULMONARY HYPERTENSION										
US	819	733	11.6%	11.6%	-	3,143	2,697	16.5%	16.5%	-
Intl	274	282	-3.2%	1.2%	-4.4%	1,140	1,117	2.0%	8.2%	-6.2%
WW	1,092	1,017	7.4%	8.7%	-1.3%	4,282	3,815	12.3%	14.1%	-1.8%
OPSUMIT										
US	385	368	4.8%	4.8%	-	1,520	1,292	17.7%	17.7%	-
Intl	160	169	-5.2%	-2.5%	-2.7%	664	681	-2.4%	1.1%	-3.5%
WW	545	536	1.7%	2.5%	-0.8%	2,184	1,973	10.7%	11.9%	-1.2%
UPTRAVI										
US	391	348	12.3%	12.3%	-	1,511	1,326	13.9%	13.9%	-
Intl	75	70	5.7%	11.2%	-5.5%	307	255	20.1%	27.3%	-7.2%
WW	465	419	11.2%	12.1%	-0.9%	1,817	1,582	14.9%	16.1%	-1.2%
OTHER PULMONARY HYPERTENSION										
US	42	18	*	*	-	112	79	41.8%	41.8%	-
Intl	40	45	-10.0%	-0.4%	-9.6%	169	182	-6.9%	8.2%	-15.1%
WW	82	61	32.3%	39.3%	-7.0%	281	260	7.9%	18.3%	-10.4%
CARDIOVASCULAR / METABOLISM / OTHER										
US	805	652	23.3%	23.3%	-	2,866	2,906	-1.4%	-1.4%	-
Intl	153	185	-17.6%	-15.1%	-2.5%	696	765	-9.1%	-7.1%	-2.0%
WW	957	837	14.3%	14.8%	-0.5%	3,562	3,671	-3.0%	-2.6%	-0.4%
XARELTO										
US	676	525	28.5%	28.5%	-	2,373	2,365	0.3%	0.3%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	676	525	28.5%	28.5%	-	2,373	2,365	0.3%	0.3%	-
OTHER										
US	130	127	1.5%	1.5%	-	494	541	-8.8%	-8.8%	-
Intl	153	185	-17.6%	-15.1%	-2.5%	696	765	-9.1%	-7.1%	-2.0%
WW	281	312	-9.8%	-8.3%	-1.5%	1,189	1,306	-8.9%	-7.8%	-1.1%
TOTAL INNOVATIVE MEDICINE										
US	**8,977**	**8,079**	**11.1%**	**11.1%**	**-**	**33,970**	**31,169**	**9.0%**	**9.0%**	**-**
Intl	**5,355**	**5,643**	**-5.1%**	**-1.0%**	**-4.1%**	**22,994**	**23,590**	**-2.5%**	**1.3%**	**-3.8%**
WW	**$ 14,332**	**$ 13,722**	**4.4%**	**6.1%**	**-1.7%**	**$ 56,964**	**54,759**	**4.0%**	**5.7%**	**-1.7%**

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD ($MM)					REPORTED SALES vs. PRIOR PERIOD ($MM)				
	FOURTH QUARTER					TWELVE MONTHS				
			% Change					% Change		
MEDTECH SEGMENT [2]	2024	2023	Reported	Operational [1]	Currency	2024	2023	Reported	Operational [1]	Currency
CARDIOVASCULAR [4]										
US	$ 1,221	971	25.8%	25.8%	-	$ 4,513	3,633	24.2%	24.2%	-
Intl	841	698	20.6%	22.0%	-1.4%	3,194	2,717	17.6%	20.9%	-3.3%
WW	2,062	1,669	23.6%	24.2%	-0.6%	7,707	6,350	21.4%	22.8%	-1.4%
ELECTROPHYSIOLOGY										
US	681	667	2.1%	2.1%	-	2,738	2,458	11.4%	11.4%	-
Intl	640	572	11.7%	13.3%	-1.6%	2,529	2,230	13.4%	17.0%	-3.6%
WW	1,321	1,239	6.6%	7.3%	-0.7%	5,267	4,688	12.3%	14.0%	-1.7%
ABIOMED										
US	308	276	11.3%	11.3%	-	1,213	1,066	13.7%	13.7%	-
Intl	77	64	19.8%	21.1%	-1.3%	284	240	18.2%	20.3%	-2.1%
WW	384	340	12.9%	13.2%	-0.3%	1,496	1,306	14.5%	14.9%	-0.4%
SHOCKWAVE [5]										
US	202	-	*	*	-	442	-	*	*	-
Intl	56	-	*	*	-	122	-	*	*	-
WW	258	-	*	*	-	564	-	*	*	-
OTHER CARDIOVASCULAR [4]										
US	31	28	11.1%	11.1%	-	120	109	10.7%	10.7%	-
Intl	68	61	12.1%	12.3%	-0.2%	260	247	5.3%	7.3%	-2.0%
WW	99	89	11.8%	12.0%	-0.2%	380	356	6.9%	8.4%	-1.5%
ORTHOPAEDICS										
US	1,460	1,425	2.4%	2.4%	-	5,689	5,525	3.0%	3.0%	-
Intl	856	843	1.6%	2.5%	-0.9%	3,470	3,417	1.5%	3.0%	-1.5%
WW	2,315	2,268	2.1%	2.5%	-0.4%	9,158	8,942	2.4%	3.0%	-0.6%
HIPS										
US	272	266	2.5%	2.5%	-	1,057	996	6.2%	6.2%	-
Intl	146	132	10.6%	11.7%	-1.1%	581	564	3.0%	4.6%	-1.6%
WW	418	398	5.2%	5.6%	-0.4%	1,638	1,560	5.0%	5.6%	-0.6%
KNEES										
US	238	242	-1.5%	-1.5%	-	922	896	2.9%	2.9%	-
Intl	160	144	10.7%	11.3%	-0.6%	623	559	11.3%	12.4%	-1.1%
WW	398	387	3.1%	3.3%	-0.2%	1,545	1,456	6.1%	6.5%	-0.4%
TRAUMA										
US	514	487	5.5%	5.5%	-	2,013	1,949	3.3%	3.3%	-
Intl	250	255	-1.9%	-0.5%	-1.4%	1,036	1,030	0.6%	2.1%	-1.5%
WW	764	741	3.0%	3.5%	-0.5%	3,049	2,979	2.3%	2.9%	-0.6%
SPINE, SPORTS & OTHER										
US	434	430	1.1%	1.1%	-	1,696	1,684	0.7%	0.7%	-
Intl	300	311	-3.6%	-2.9%	-0.7%	1,230	1,263	-2.6%	-1.2%	-1.4%
WW	735	742	-0.9%	-0.6%	-0.3%	2,926	2,947	-0.7%	-0.1%	-0.6%

	REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER					REPORTED SALES vs. PRIOR PERIOD ($MM) TWELVE MONTHS				
			% Change					% Change		
	2024	2023	Reported	Operational (1)	Currency	2024	2023	Reported	Operational (1)	Currency
SURGERY										
US	**1,038**	**1,047**	-0.9%	-0.9%	-	**4,003**	**4,031**	-0.7%	-0.7%	-
Intl	**1,469**	**1,484**	-1.0%	1.4%	-2.4%	**5,842**	**6,006**	-2.7%	0.6%	-3.3%
WW	**2,507**	**2,530**	-0.9%	0.4%	-1.3%	**9,845**	**10,037**	-1.9%	0.1%	-2.0%
ADVANCED										
US	**478**	**468**	2.0%	2.0%	-	**1,838**	**1,833**	0.2%	0.2%	-
Intl	**673**	**698**	-3.6%	-1.6%	-2.0%	**2,650**	**2,837**	-6.6%	-3.5%	-3.1%
WW	**1,151**	**1,167**	-1.4%	-0.1%	-1.3%	**4,488**	**4,671**	-3.9%	-2.0%	-1.9%
GENERAL										
US	**560**	**579**	-3.1%	-3.1%	-	**2,165**	**2,198**	-1.5%	-1.5%	-
Intl	**795**	**785**	1.4%	4.0%	-2.6%	**3,192**	**3,168**	0.8%	4.3%	-3.5%
WW	**1,357**	**1,364**	-0.5%	1.0%	-1.5%	**5,358**	**5,366**	-0.2%	2.0%	-2.2%
VISION										
US	**509**	**487**	4.5%	4.5%	-	**2,128**	**2,086**	2.0%	2.0%	-
Intl	**794**	**721**	10.2%	12.2%	-2.0%	**3,018**	**2,986**	1.1%	3.7%	-2.6%
WW	**1,303**	**1,208**	7.9%	9.1%	-1.2%	**5,146**	**5,072**	1.5%	3.0%	-1.5%
CONTACT LENSES / OTHER										
US	**396**	**374**	6.0%	6.0%	-	**1,684**	**1,626**	3.6%	3.6%	-
Intl	**541**	**508**	6.4%	8.5%	-2.1%	**2,049**	**2,076**	-1.3%	1.8%	-3.1%
WW	**937**	**882**	6.3%	7.4%	-1.1%	**3,733**	**3,702**	0.8%	2.6%	-1.8%
SURGICAL										
US	**113**	**114**	-0.4%	-0.4%	-	**444**	**460**	-3.4%	-3.4%	-
Intl	**252**	**212**	19.3%	21.1%	-1.8%	**969**	**910**	6.5%	8.2%	-1.7%
WW	**365**	**326**	12.4%	13.6%	-1.2%	**1,413**	**1,370**	3.2%	4.3%	-1.1%
TOTAL MEDTECH										
US	**4,227**	**3,930**	**7.6%**	**7.6%**	**-**	**16,332**	**15,275**	**6.9%**	**6.9%**	**-**
Intl	**3,961**	**3,743**	**5.8%**	**7.6%**	**-1.8%**	**15,525**	**15,125**	**2.6%**	**5.4%**	**-2.8%**
WW	**$ 8,188**	**$ 7,673**	**6.7%**	**7.6%**	**-0.9%**	**$ 31,857**	**30,400**	**4.8%**	**6.2%**	**-1.4%**

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Reported as U.S. sales
(4) Previously referred to as Interventional Solutions
(5) Acquired on May 31, 2024

Supplemental Sales Information (Unaudited)

(Dollars in Millions)

	FOURTH QUARTER						TWELVE MONTHS					
				Percent Change						Percent Change		
		2024	2023	Total	Operations	Currency		2024	2023	Total	Operations	Currency
Innovative Medicine												
U.S.	$	**8,977**	**8,079**	11.1	11.1	-	$	**33,970**	**31,169**	9.0	9.0	-
International		**5,355**	**5,643**	(5.1)	(1.0)	(4.1)		**22,994**	**23,590**	(2.5)	1.3	(3.8)
Worldwide		**14,332**	**13,722**	4.4	6.1	(1.7)		**56,964**	**54,759**	4.0	5.7	(1.7)
COVID-19 Vaccine												
U.S.		**-**	**-**	-	-	-		**-**	**-**	-	-	-
International		**-**	**44**	*	*	*		**198**	**1,117**	(82.4)	(82.4)	0.0
Worldwide		**-**	**44**	*	*	*		**198**	**1,117**	(82.4)	(82.4)	0.0
Innovative Medicine excluding COVID-19 Vaccine												
U.S.		**8,977**	**8,079**	11.1	11.1	-		**33,970**	**31,169**	9.0	9.0	-
International		**5,355**	**5,599**	(4.4)	(0.3)	(4.1)		**22,796**	**22,473**	1.4	5.5	(4.1)
Worldwide		**14,332**	**13,678**	4.8	6.5	(1.7)		**56,766**	**53,642**	5.8	7.5	(1.7)
Worldwide												
U.S.		**13,204**	**12,009**	10.0	10.0	-		**50,302**	**46,444**	8.3	8.3	-
International		**9,316**	**9,386**	(0.7)	2.5	(3.2)		**38,519**	**38,715**	(0.5)	2.9	(3.4)
Worldwide		**22,520**	**21,395**	5.3	6.7	(1.4)		**88,821**	**85,159**	4.3	5.9	(1.6)
COVID-19 Vaccine												
U.S.		**-**	**-**	-	-	-		**-**	**-**	-	-	-
International		**-**	**44**	*	*	*		**198**	**1,117**	(82.4)	(82.4)	0.0
Worldwide		**-**	**44**	*	*	*		**198**	**1,117**	(82.4)	(82.4)	0.0
Worldwide												
U.S.		**13,204**	**12,009**	10.0	10.0	-		**50,302**	**46,444**	8.3	8.3	-
International		**9,316**	**9,342**	(0.3)	2.9	(3.2)		**38,321**	**37,598**	1.9	5.5	(3.6)
Worldwide excluding COVID-19 Vaccine	$	**22,520**	**21,351**	5.5	6.9	(1.4)	$	**88,623**	**84,042**	5.5	7.0	(1.5)
Europe	$	**4,921**	**4,962**	(0.8)	(0.2)	(0.6)	$	**20,212**	**20,410**	(1.0)	(0.6)	(0.4)
Europe COVID-19 Vaccine Sales		**-**	**44**	*	*	*		**198**	**1,117**	(82.4)	(82.4)	0.0
Europe excluding COVID-19 Vaccine Sales	$	**4,921**	**4,918**	0.1	0.7	(0.6)	$	**20,014**	**19,293**	3.7	4.1	(0.4)

* Percentage greater than 100% or not meaningful

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures) — FOURTH QUARTER

	2024 Amount	2024 Percent to Sales	2023 Amount	2023 Percent to Sales	Percent Increase (Decrease)
Sales to customers	$ 22,520	100.0	$ 21,395	100.0	5.3
Cost of products sold	7,128	31.6	6,798	31.8	4.9
Gross Profit	15,392	68.4	14,597	68.2	5.4
Selling, marketing and administrative expenses	6,453	28.6	5,810	27.1	11.1
Research and development expense	5,298	23.5	4,480	20.9	18.3
In-process research and development impairments	17	0.1	58	0.3	
Interest (income) expense, net	(144)	(0.6)	(212)	(1.0)	
Other (income) expense, net	(161)	(0.7)	(421)	(2.0)	
Restructuring	42	0.2	56	0.3	
Earnings before provision for taxes on income	3,887	17.3	4,826	22.6	(19.5)
Provision for taxes on income	456	2.1	694	3.3	(34.3)
Net earnings from Continuing Operations	$ 3,431	15.2	$ 4,132	19.3	(17.0)
Net earnings/(loss) from Discontinued Operations, net of tax	-		(83)		
Net earnings	$ 3,431		$ 4,049		
Net earnings per share (Diluted) from Continuing Operations	$ 1.41		$ 1.70		(17.1)
Net earnings/(loss) per share (Basic) from Discontinued Operations*	$ -		$ (0.03)		
Average shares outstanding (Diluted)	2,427.1		2,430.7		
Effective tax rate from Continuing Operations	11.7 %		14.4 %		
Adjusted earnings from Continuing Operations before provision for taxes and net earnings [1]					
Earnings before provision for taxes on income from Continuing Operations	$ 5,421	24.1	$ 6,237	29.2	(13.1)
Net earnings from Continuing Operations	$ 4,946	22.0	$ 5,562	26.0	(11.1)
Net earnings per share (Diluted) from Continuing Operations	$ 2.04		$ 2.29		(10.9)
Effective tax rate from Continuing Operations	8.8 %		10.8 %		

* Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive.

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	TWELVE MONTHS				
	2024		2023		Percent
		Percent		Percent	Increase
	Amount	to Sales	Amount	to Sales	(Decrease)
Sales to customers	$ 88,821	100.0	$ 85,159	100.0	4.3
Cost of products sold	27,471	30.9	26,553	31.2	3.5
Gross Profit	61,350	69.1	58,606	68.8	4.7
Selling, marketing and administrative expenses	22,869	25.7	21,512	25.2	6.3
Research and development expense	17,232	19.4	15,085	17.7	14.2
In-process research and development impairments	211	0.2	313	0.4	
Interest (income) expense, net	(577)	(0.6)	(489)	(0.6)	
Other (income) expense, net	4,694	5.3	6,634	7.8	
Restructuring	234	0.3	489	0.6	
Earnings before provision for taxes on income	16,687	18.8	15,062	17.7	10.8
Provision for taxes on income	2,621	3.0	1,736	2.1	51.0
Net earnings from Continuing Operations	$ 14,066	15.8	$ 13,326	15.6	5.6
Net earnings from Discontinued Operations, net of tax	-		21,827		
Net earnings	$ 14,066		$ 35,153		
Net earnings per share (Diluted) from Continuing Operations	$ 5.79		$ 5.20		11.3
Net earnings per share (Diluted) from Discontinued Operations	$ -		$ 8.52		
Average shares outstanding (Diluted)	2,429.4		2,560.4		
Effective tax rate from Continuing Operations	15.7 %		11.5 %		
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income from Continuing Operations	$ 28,979	32.6	$ 29,811	35.0	(2.8)
Net earnings from Continuing Operations	$ 24,242	27.3	$ 25,409	29.8	(4.6)
Net earnings per share (Diluted) from Continuing Operations	$ 9.98		$ 9.92		0.6
Effective tax rate from Continuing Operations	16.3 %		14.8 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
FOURTH QUARTER 2024 ACTUAL vs. 2023 ACTUAL

	Segments		
	Innovative Medicine	MedTech	Total
WW As Reported	**4.4%**	**6.7%**	**5.3%**
U.S.	11.1%	7.6%	10.0%
International	(5.1)%	5.8%	(0.7)%
WW Currency	**(1.7)**	**(0.9)**	**(1.4)**
U.S.	-	-	-
International	(4.1)	(1.8)	(3.2)
WW Operational	**6.1%**	**7.6%**	**6.7%**
U.S.	11.1%	7.6%	10.0%
International	(1.0)%	7.6%	2.5%
Shockwave		**(3.4)**	**(1.2)**
U.S.		(5.1)	(1.7)
International		(1.5)	(0.6)
All Other Acquisitions and Divestitures (A&D)	**0.2**	**0.4**	**0.2**
U.S.	0.1	0.8	0.3
International	0.3	0.0	0.1
WW Adjusted Operational Ex A&D	**6.3%**	**4.6%**	**5.7%**
U.S.	11.2%	3.3%	8.6%
International	(0.7)%	6.1%	2.0%
COVID-19 Vaccine	**0.4**		**0.2**
U.S.	0.0		0.0
International	0.7		0.4
WW Adjusted Operational Ex A&D & COVID-19 Vaccine	**6.7%**	**4.6%**	**5.9%**
U.S.	11.2%	3.3%	8.6%
International	0.0%	6.1%	2.4%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
TWELVE MONTHS 2024 ACTUAL vs. 2023 ACTUAL

	Segments		
	Innovative Medicine	MedTech	Total
WW As Reported	**4.0%**	**4.8%**	**4.3%**
U.S.	9.0%	6.9%	8.3%
International	(2.5)%	2.6%	(0.5)%
WW Currency	**(1.7)**	**(1.4)**	**(1.6)**
U.S.	-	-	-
International	(3.8)	(2.8)	(3.4)
WW Operational	**5.7%**	**6.2%**	**5.9%**
U.S.	9.0%	6.9%	8.3%
International	1.3%	5.4%	2.9%
Shockwave		**(1.9)**	**(0.7)**
U.S.		(2.9)	(1.0)
International		(0.8)	(0.3)
All Other Acquisitions and Divestitures (A&D)	**0.1**	**0.4**	**0.2**
U.S.	0.1	0.8	0.3
International	0.2	0.1	0.1
WW Adjusted Operational Ex A&D	**5.8%**	**4.7%**	**5.4%**
U.S.	9.1%	4.8%	7.6%
International	1.5%	4.7%	2.7%
COVID-19 Vaccine	**1.8**		**1.1**
U.S.	0.0		0.0
International	4.2		2.6
WW Adjusted Operational Ex A&D & COVID-19 Vaccine	**7.6%**	**4.7%**	**6.5%**
U.S.	9.1%	4.8%	7.6%
International	5.7%	4.7%	5.3%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Fourth Quarter		Twelve Months Ended	
(Dollars in Millions Except Per Share Data)	2024	2023	2024	2023
Net Earnings from Continuing Operations, after tax- as reported	**$3,431**	**$4,132**	**$14,066**	**$13,326**
Pre-tax Adjustments				
Litigation related	(16)	166	5,450	7,152
Intangible Asset Amortization expense	1,171	1,148	4,526	4,532
COVID-19 Vaccine related costs [1]	23	10	100	663
Restructuring related [2]	62	139	269	798
Medical Device Regulation [3]	47	88	204	311
Acquisition, integration and divestiture related	298	237	1,226	339
(Gains)/losses on securities	(68)	(435)	306	641
IPR&D impairments	17	58	211	313
Tax Adjustments				
Tax impact on special item adjustments [4]	(80)	75	(2,135)	(2,694)
Tax legislation and other tax related	61	(56)	19	28
Adjusted Net Earnings from Continuing Operations, after tax	**$4,946**	**$5,562**	**$24,242**	**$25,409**
Average shares outstanding (Diluted)	2,427.1	2,430.7	2,429.4	2,560.4
Adjusted net earnings per share from Continuing Operations (Diluted)	**$2.04**	**$2.29**	**$9.98**	**$9.92**
Operational adjusted net earnings per share from Continuing Operations (Diluted)	**$2.05**		**$9.99**	

Notes:

1 COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments which was completed in Q4 2024.

2 In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million Q4 2024 YTD and $55 million in the fiscal fourth quarter of 2023 ($479 million Q4 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.

In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) and $84 million in the fiscal fourth quarter of 2023 ($319 million Q4 2023 YTD) primarily includes costs related to the market and product exits.

3 European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance. The implementation was substantially completed as of Q4 2024, and ongoing costs will be reflected in MedTech's operating results beginning in 2025.

4 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q4 QTD - Income Before Tax* and Research & Development Expense by Segment
Dollars in Millions

		Innovative Medicine		MedTech		Unallocated		Worldwide Total	
		2024	2023	2024	2023	2024	2023	2024	2023
Reported Income Before Tax by Segment From Continuing Operations	$	4,009	4,238	72	404	(194)	184	3,887	4,826
% to Sales		***28.0%***	***30.9%***	***0.9%***	***5.3%***	***-0.9%***	***0.9%***	***17.3%***	***22.6%***
Intangible asset amortization expense		685	747	486	401	-	-	1,171	1,148
In-process research and development impairments		17	-	-	58	-	-	17	58
Litigation related		(41)	17	(29)	149	54	-	(16)	166
Loss/(gain) on securities		(50)	(112)	(18)	(59)	-	(264)	(68)	(435)
Restructuring related		2	55	60	84	-	-	62	139
Acquisition, integration and divestiture related		12	175	268	62	18	-	298	237
Medical Device Regulation		-	-	47	88	-	-	47	88
COVID-19 Vaccine related costs		23	10	-	-	-	-	23	10
Adjusted Income Before Tax by Segment From Continuing Operations	$	4,657	5,130	886	1,187	(122)	(80)	5,421	6,237
% to Sales		***32.5%***	***37.4%***	***10.8%***	***15.5%***	***-0.5%***	***-0.4%***	***24.1%***	***29.2%***

*Estimated as of 1/22/2025

		Innovative Medicine 2024	Innovative Medicine 2023	MedTech 2024	MedTech 2023	Unallocated 2024	Unallocated 2023	Worldwide Total 2024	Worldwide Total 2023
As Reported Research and development expense**	$	3,698	3,357	1,600	1,123			5,298	4,480
% to Sales		***25.8%***	***24.5%***	***19.5%***	***14.6%***			***23.5%***	***20.9%***

**Includes the following Acquired IPR&D:	MedTech 2024	MedTech 2023	Worldwide Total 2024	Worldwide Total 2023
Laminar - Q4 2023		390		390
V-Wave - Q4 2024	540		540	
Total	540	390	540	390

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q4 YTD - Income Before Tax* and Research & Development Expense by Segment
Dollars in Millions

		Innovative Medicine		MedTech		Unallocated		Worldwide Total	
		2024	2023	2024	2023	2024	2023	2024	2023
Reported Income Before Tax by Segment From Continuing Operations	$	18,919	18,246	3,740	4,669	(5,972)	(7,853)	16,687	15,062
% to Sales		***33.2%***	***33.3%***	***11.7%***	***15.4%***	***-6.7%***	***-9.2%***	***18.8%***	***17.7%***
Intangible asset amortization expense		2,772	2,983	1,754	1,549	-	-	4,526	4,532
In-process research and development impairments		211	206	-	107	-	-	211	313
Litigation related		358	(108)	(14)	190	5,106	7,070	5,450	7,152
Loss/(gain) on securities		(76)	362	30	(102)	352	381	306	641
Restructuring related		102	479	167	319	-	-	269	798
Acquisition, integration and divestiture related		66	175	1,015	164	145	-	1,226	339
Medical Device Regulation		-	-	204	311	-	-	204	311
COVID-19 Vaccine related costs		100	663	-	-	-	-	100	663
Adjusted Income Before Tax by Segment From Continuing Operations	$	22,452	23,006	6,896	7,207	(369)	(402)	28,979	29,811
% to Sales		***39.4%***	***42.0%***	***21.6%***	***23.7%***	***-0.4%***	***-0.5%***	***32.6%***	***35.0%***

*Estimated as of 1/22/2025

		Innovative Medicine 2024	Innovative Medicine 2023	MedTech 2024	MedTech 2023	Unallocated 2024	Unallocated 2023	Worldwide Total 2024	Worldwide Total 2023
As Reported Research and development expense**	$	13,529	11,963	3,703	3,122			17,232	15,085
% to Sales		***23.8%***	***21.8%***	***11.6%***	***10.3%***			***19.4%***	***17.7%***
**Includes the following Acquired IPR&D:									
Laminar - Q4 2023					390				390
Yellow Jersey (NM26 bispecific antibody) - Q3 2024		1,250						1,250	
V-Wave -Q4 2024				540				540	
Total		1,250		540	390			1,790	390

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

Quarter to Date

	Fourth Quarter Dec. 29, 2024 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Fourth Quarter Dec. 29, 2024 Non-GAAP
Cost of products sold	$ 7,128	(1,162)			(20)	(153)		(18)	-	-	5,775
Selling, marketing and admin expenses	6,453							(4)			6,449
Research and development expense	5,298					-		(25)	(6)		5,267
Other (Income) / Expense	(161)	(9)	16		-	(145)	68		(17)		(248)
In-process research and development impairments	17			(17)		-					-
Restructuring	42				(42)						-
Provision for taxes on income	456	171	(158)	4	3	80	(34)	9	5	(61)	475
Net Earnings from Continuing Operations	3,431	1,000	142	13	59	218	(34)	38	18	61	4,946

	Fourth Quarter Dec. 31, 2023 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Fourth Quarter Dec. 31, 2023 Non-GAAP
Cost of products sold	$ 6,798	(1,131)			(83)			(42)	(12)	-	5,530
Selling, marketing and admin expenses	5,810							(8)			5,802
Research and development expense	4,480					(16)		(38)	(1)		4,425
Other (Income) / Expense	(421)	(17)	(166)		-	(221)	435		3		(387)
In-process research and development impairments	58			(58)							-
Restructuring	56				(56)						-
Provision for taxes on income	694	175	(134)	13	16	30	(191)	16	-	56	675
Net Earnings from Continuing Operations	4,132	973	300	45	123	207	(244)	72	10	(56)	5,562

Year to Date

	Twelve Months Dec. 29, 2024 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Twelve Months Dec. 29, 2024 Non-GAAP
Cost of products sold	$ 27,471	(4,517)			(35)	(359)		(84)	(8)		22,468
Selling, marketing and admin expenses	22,869							(16)	-		22,853
Research and development expense	17,232					(69)		(104)	(25)		17,034
Other (Income) / Expense	4,694	(9)	(5,450)		-	(798)	(306)		(67)		(1,936)
In-process research and development impairments	211			(211)	-	-	-		-		-
Restructuring	234				(234)						-
Provision for taxes on income	2,621	644	1,066	47	45	302	(29)	38	22	(19)	4,737
Net Earnings from Continuing Operations	14,066	3,882	4,384	164	224	924	335	166	78	19	24,242

	Twelve Months Dec. 31, 2023 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Twelve Months Dec. 31, 2023 Non-GAAP
Cost of products sold	$ 26,553	(4,511)			(309)			(133)	(189)		21,411
Selling, marketing and admin expenses	21,512							(29)			21,483
Research and development expense	15,085					(32)		(149)	(99)		14,805
Other (Income) / Expense	6,634	(21)	(7,152)		-	(307)	(641)		(375)		(1,862)
In-process research and development impairments	313			(313)	-						-
Restructuring	489				(489)						-
Provision for taxes on income	1,736	707	1,505	70	157	52	(9)	57	155	(28)	4,402
Net Earnings from Continuing Operations	13,326	3,825	5,647	243	641	287	650	254	508	28	25,409